Solitary plasmacytoma of bone and soft tissue

Bolek, Timothy W.; Marcus, Robert B.; Mendenhall, Nancy P.

doi:10.1016/s0360-3016(96)00334-3

Cited by 180 publications

(133 citation statements)

References 14 publications

Supporting

Mentioning

117

Contrasting

Order By: Relevance

“…[8][9][10][11] We also demonstrated a relation between the presence of myeloma protein at presentation and the risk of progression to myeloma, which agrees with our previously published data as well as others on the correlation between persistence of myeloma protein after radiation and the development of myeloma. 1,12 Dingli et al 13 also reported on the value a persistent serum protein level 5 g/L as a risk factor for progression along with an abnormal serum immunoglobulin-free light chain ratio at diagnosis.…”

Section: Discussionsupporting

confidence: 92%

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

100

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P ¼ .021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P ¼ .016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P ¼ .048 and P ¼ .29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P ¼ .274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis. Cancer 2011;117:4468-

show abstract

Section: Discussionsupporting

confidence: 92%

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

100

View full text Add to dashboard Cite

show abstract

“…Data published so far are inconsistent: Significantly different OS rates were found by Ozsahin et al, who described 10-year overall survival rates of 72% for EP and 52% for SBP (p=0.04) [4], and Tsang et al, who reported 8-year overall survival rates of 70% or 33%, respectively (p=0.023). In contrast, neither Bolek et al [12] nor Jyothirmay et al [13] could detect a significant difference in OS.…”

Section: Overall Survivalmentioning

confidence: 82%

“…For EP, significantly better local control was reported for doses >45 Gy (100% 5-year LCR vs. 55% for <45 Gy) [15]. Considering the low treatment toxicity, doses of 40-50 Gy seem to be a general consensus for SBP [1,12,16] and of 40-60…”

Section: Influence Of Dosementioning

confidence: 97%

Radiotherapy of solitary plasmacytoma

et al. 2011

View full text Add to dashboard Cite

International audienceSolitary plasmacytoma of the bone (SBP) or extramedullary plasmacytoma (EP) are rare neoplasms amenable to local radiotherapy. In this retrospective analysis, we report the University Heidelberg experience in the treatment of solitary plasmacytoma. From 1995 to 2008, 18 patients were treated with local radiotherapy. Ten patients suffered from SBP, eight patients showed a single extramedullary lesion. Local radiotherapy with a median dose of 45 Gy yielded excellent local control with only one patient suffering from local relapse. SBP and EP had significantly different 5-year multiple myeloma-free survival rates of 36.8% and 86.7%, respectively. However, no significant difference in overall survival could be detected. Radiotherapy can achieve excellent local control of solitary plasmacytoma. Progression to multiple myeloma, especially in the case of SBP, remains to be addressed by further studies

show abstract

“…The majority of patients with apparent SBP continue to develop myeloma and approximately 5% of all patients with multiple myeloma have an initial diagnosis of solitary plasmacytoma (Bolek et al 1996).…”

Section: Natural History and Prognosismentioning

confidence: 99%